AU7257696A - Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 - Google Patents

Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12

Info

Publication number
AU7257696A
AU7257696A AU72576/96A AU7257696A AU7257696A AU 7257696 A AU7257696 A AU 7257696A AU 72576/96 A AU72576/96 A AU 72576/96A AU 7257696 A AU7257696 A AU 7257696A AU 7257696 A AU7257696 A AU 7257696A
Authority
AU
Australia
Prior art keywords
interleukin
inhibitors
methods
autoimmune disease
treating autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72576/96A
Inventor
Brian L. Kelsall
Thomas Marth
Warren Strober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Government filed Critical US Department of Health and Human Services
Publication of AU7257696A publication Critical patent/AU7257696A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU72576/96A 1996-10-11 1996-10-11 Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 Abandoned AU7257696A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/016007 WO1998016248A1 (en) 1996-10-11 1996-10-11 Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12

Publications (1)

Publication Number Publication Date
AU7257696A true AU7257696A (en) 1998-05-11

Family

ID=22255916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72576/96A Abandoned AU7257696A (en) 1996-10-11 1996-10-11 Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12

Country Status (2)

Country Link
AU (1) AU7257696A (en)
WO (1) WO1998016248A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7279459B2 (en) 2001-01-04 2007-10-09 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
CA2353520C (en) * 1998-12-09 2006-04-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU1592801A (en) * 1999-11-12 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of treating inflammatory bowel disease using cholera toxin B subunit
US7041296B1 (en) 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
RU2497545C2 (en) 2008-03-18 2013-11-10 Эбботт Лэборетриз Method of treating psoriasis (versions)
MX2012003138A (en) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Methods for treating psoriasis.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121096A1 (en) * 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines

Also Published As

Publication number Publication date
WO1998016248A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
AU5439996A (en) Compositions and methods for treating pain
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
AU6045298A (en) Method and device for soft tissue modification
EP0967919A4 (en) Implantation instrument and method
IL117607A0 (en) Surgical stapler and method of surgical fastening
AU5308796A (en) Soft tissue anchor and method
AU4339197A (en) Fastening device and method of use
EP1765179A4 (en) Tissue remover and method
AU5036198A (en) Methods and devices for collection of soft tissue
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
PL318128A1 (en) Polymer-polyol and method of obtaining polymer-polyols
IL129389A0 (en) Compounds and methods for diagnsosis of tuberculosis
AU7257696A (en) Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
AU5605398A (en) Novel methods and compositions for treatment of autoimmune diseases
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
AU9505898A (en) Device and method for mandibular fixation
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
AU3389197A (en) $(d)-erythroid kruppel-like factors and methods of use
AU4027097A (en) Method of treatment
ZA964107B (en) Enzyme degrading rhamnogalacturonane ii methods for obtaining said enzyme and rhamnogalacturonane ii and use of said enzyme
AU6257998A (en) Methods for diagnosing and treating autoimmune disease
AU4289896A (en) Artificial nail and method for making same
AU3423397A (en) Therapeutic methods and compositions for use therein
AU3149297A (en) Methods of treating hypertension
IL125523A0 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)